MARKET

SAVA

SAVA

Cassava Sciences
NASDAQ
1.845
-0.015
-0.82%
Opening 10:18 05/14 EDT
OPEN
1.860
PREV CLOSE
1.860
HIGH
1.950
LOW
1.830
VOLUME
320.15K
TURNOVER
0
52 WEEK HIGH
42.20
52 WEEK LOW
1.150
MARKET CAP
89.11M
P/E (TTM)
-1.2235
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SAVA last week (0505-0509)?
Weekly Report · 2d ago
Cassava Sciences Shifts Focus to TSC-Related Epilepsy
TipRanks · 5d ago
Based on the provided financial report articles, the title of the article is: "CASSAVA SCIENCES INC. (0001069530) 10-Q for the quarterly period ended March 31, 2025" This title indicates that the article is a quarterly report (10-Q) filed by Cassava Sciences Inc. (0001069530) with the Securities and Exchange Commission (SEC) for the period ended March 31, 2025.
Press release · 5d ago
Cassava Sciences Q1 EPS $(0.48) Down From $(0.43) YoY
Benzinga · 6d ago
CASSAVA REPORTS Q1 2025 FINANCIALS RESULTS, PROVIDES BUSINESS UPDATE
Reuters · 6d ago
CASSAVA SCIENCES INC - REDUCES WORKFORCE BY 33% IN Q1 2025
Reuters · 6d ago
*Cassava Sciences 1Q Loss/Shr 48c >SAVA
Dow Jones · 6d ago
Press Release: Cassava Reports Q1 2025 Financials -2-
Dow Jones · 6d ago
More
About SAVA
More
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Recently
Symbol
Price
%Change

Webull offers Cassava Sciences Inc stock information, including NASDAQ: SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.